Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-methylthiofentanyl is a synthetic opioid analgesic and a structural analogue of fentanyl. Like other fentanyl analogues, it acts as an agonist at the mu-opioid receptor, producing potent analgesic effects as well as typical opioid side effects such as itching, nausea, and potentially life-threatening respiratory depression. It was briefly sold on the illicit market in the early 1980s before being controlled under drug laws due to its high abuse potential and risk profile. There is no accepted medical use for this compound in the United States or most other countries[1][2][3]. Its mechanism of action involves binding to mu-opioid receptors in the central nervous system, leading to inhibition of pain pathways and altered neurotransmitter release[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-methylthiofentanyl.